Inflammatory Bowel Disease (IBD) Treatment Market Report

Inflammatory Bowel Disease (IBD) Treatment Market Analysis, Market Size, Disease Indication Analysis, Drug Class Analysis, Distribution Channel Analysis, Regional Outlook, Competitive Strategies, And Segment Forecasts, 2019 To 2025

  • Published Date: ---
  • Base Year for Estimate:
  • Report ID: GVR5650
  • Format: Electronic (PDF)
  • Historical Data:
  • Number of Pages: 0

Global inflammatory bowel disease treatment market is estimated to increase at a significant rate over the forecast period owing to the increase in intake of unhealthy food and beverages along with the stressfull lifestyle and lack of exercise. Inflammatory bowel disease is generally caused when immune system attacks harmless virus, bacteria in the intestine.

Increasing prevelace of inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis is expected to add fuel to the market. According to an article published in 2017 in Elsevier Limited, the prevelance of inflammatory bowel disease exceeded 0.3% in North America, and Europe. In addition, the highest prevelance in Europe of Crohn’s disease was found to be 322 per 100,000 in Germany whereas for ulcerative colitis it was found to be 505 per 100,000 in Norway.

Based on disease indication, the overall market is segmented into ulcerative colitis, and Crohn’s disease. The rising incidence and prevelance of these diseases are expected to drive the market. Increase in the prevalence of Crohn’s disease in developing countries is due to industrialization, and other environmental factors such as pollution, food additives and infections. As per an article published in The New England Journal of Medicine (NEJM) in 2017, a study was conducted in Sweden which illustrated that the magnitude of ulcerative colitis was increasing, accounting for increased annual incidence rates from 4 to 18 per 100,000 patients.

On the basis of drug class, the market is segmented into anti-inflammatory drugs, immune system supressors, and others. Strong presence of pipeline products is one of the major factors anticipated to propel market growth over the forecast period. In addition, commercialization of biosimilars for the treatment of inflammatory bowel diseases are expected to boost the market. Based on the distribution channel, the inflammatory bowel disease treatment market is segmented into hopsital pharmacy, online pharmacy and retail pharmacy.

According to the region, the market is segmented into North America, Asia-Pacific, Europe, Latin America, and Middle East Asia. North America is estimated to dominate the market owing to the presence of key market players and huge patient population. Major industry participants include Johnson & Johnson Services Inc.; Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Celltrion Healthcare Co., Ltd., CELGENE CORPORATION, COSMO PHARMACEUTICALS, Innovate Biopharmaceuticals, Gilead and UCB S.A.

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $4,950
Multi User (2-5) - $5,950
Enterprise Access - $7,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified